This Article Full Text Full Text (PDF) Correction (v13,p3759) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brandt, B. Articles by Buerger, H. Search for Related Content PubMed PubMed Citation Articles by Brandt, B. Articles by Buerger, H.

Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response

Authors' Affiliations: ¹ Institute for Tumor Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany and ² Gerhard-Domagk Institute of Pathology, University Medical Centre Münster, Münster, Germany

Requests for reprints: Burkhard Brandt, Institut für Tumorbiologie, University Medical Centre, Centre for Experimental Medicine, Martinistr. 52, 20246 Hamburg, Germany. Phone: 49-251-8347226; Fax: 49-251-8347226; E-mail: bu.brandt{at}uke.uni-hamburg.de.

The epidermal growth factor receptor (EGFR) plays a crucial role in growth, differentiation, and motility of normal as well as cancer cells. For predictive cancer diagnostics and therapeutic targeting of EGFR, it is important to know how the expression level of EGFR is controlled and related to receptor signaling. A novel transcriptional regulation mechanism has been described that depends on the length of a CA repeat in intron 1 [CA simple sequence repeat 1 (CA SSR I)] of the EGFR gene. Thereby, the number of CA repeats is inversely correlated to pre-mRNA synthesis. Indirect evidence for the importance of this mechanism includes the preferential occurrence of amplifications in cancer tissue harboring short CA repeats in this sequence and the discovery of distinct alleles in young breast cancer patients with a family history of the disease and in Japanese breast cancer patients. It can be postulated that the length of the CA repeat influences DNA bendability and, in consequence, the binding of repressor proteins. In summary, it seems that the CA SSR I represents an inherited variable for response to anti-EGFR therapies that could be determined before therapy. Moreover, the potential for synergistic effects with other polymorphism [e.g., EGFR R497K (HER-1 497K) and CCND1 A870G] leading to a simultaneous increase of EGFR signaling activity and expression should be investigated. From a practical perspective, assessment of the CA SSR I number of CA dinucleotide repeats as a predictor for clinical outcome is very attractive because it is a constant feature that does not change over time and can be easily measured in normal and cancer tissues (blood cells, skin, and tumor biopsies) in an assay that is technically simple, objective, and even quantitative.

This article has been cited by other articles:

				F. Graziano, A. Ruzzo, F. Loupakis, E. Canestrari, D. Santini, V. Catalano, R. Bisonni, U. Torresi, I. Floriani, G. Schiavon, et al. Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer J. Clin. Oncol., March 20, 2008; 26(9): 1427 - 1434. [Abstract] [Full Text] [PDF]

				M. Loprevite, M. Tiseo, M. Chiaramondia, M. Capelletti, C. Bozzetti, B. Bortesi, N. Naldi, R. Nizzoli, P. Dadati, A. Kunkl, et al. Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non Small Cell Lung Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6518 - 6526. [Abstract] [Full Text] [PDF]

				R. Rosell, M. Taron, N. Reguart, D. Isla, and T. Moran Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway Clin. Cancer Res., December 15, 2006; 12(24): 7222 - 7231. [Abstract] [Full Text] [PDF]